top of page
IMM_Friends on Road Trip_edited_edited_edited_edited_edited.jpg

Driving clinical impact

Faster, leaner, de-risked

Galenicap is a specialty pharma company focused on the development of value-added medicines across large, high-impact therapeutic areas. Our mission is to improve patient outcomes and expand affordable access to innovative treatment solutions, worldwide.

Product portfolio

Galenicap is building a scalable product development engine turning validated science into real solutions for patients. Our approach combines strategic product selection, cost-efficient and agile development, and focused investment to accelerate the path toward clinical validation.

​

Today, we have 10+ active programs in multiple, high-impact indications, including CNS, stroke, oncology, cardiovascular conditions, infectious diseases, obesity, and women’s health.

We turn validated science - often trapped in academia or missed commercially - in real solutions for patients

Everyone counts

Our vision is to improve healthcare by expanding access to affordable, patient-centered medicines.

 

At Galenicap, we are deeply committed to responsible business practices rooted in strong governance and meaningful social impact. We champion health equity, fair medicine pricing, transparent leadership, and a culture of diversity and inclusion.

 

We are proud that our team members, collaborators, partners, and shareholders are united in upholding these values.

Latest news & events

Galenicap BV and Neurevo GmbH created Glicothera BV, a specialty pharma focused on a new neuroprotective agent for stroke

May 13, 2025

Galenicap co-founded Aclathera BV, a specialty pharma dedciated to the development of new cancer treatments

March 28, 2025

Clozathera BV (a Galenicap company) completes financing round to support Phase 1 clinical trial for its lead product

January 6, 2025

bottom of page